ATE273990T1 - Adenosin a1-rezeptor agonisten - Google Patents

Adenosin a1-rezeptor agonisten

Info

Publication number
ATE273990T1
ATE273990T1 AT98965151T AT98965151T ATE273990T1 AT E273990 T1 ATE273990 T1 AT E273990T1 AT 98965151 T AT98965151 T AT 98965151T AT 98965151 T AT98965151 T AT 98965151T AT E273990 T1 ATE273990 T1 AT E273990T1
Authority
AT
Austria
Prior art keywords
adenosine
receptor agonists
agonists
receptor
Prior art date
Application number
AT98965151T
Other languages
English (en)
Inventor
Richard Peter Charles Cousins
Brian Cox
Colin David Eldred
Andrew Michael Kenneth Pennell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE273990T1 publication Critical patent/ATE273990T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98965151T 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten ATE273990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007021 WO1999024449A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (1)

Publication Number Publication Date
ATE273990T1 true ATE273990T1 (de) 2004-09-15

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965151T ATE273990T1 (de) 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten

Country Status (29)

Country Link
US (1) US6455510B1 (de)
EP (2) EP1457495A1 (de)
JP (1) JP2001522857A (de)
KR (1) KR20010031875A (de)
CN (1) CN1285843A (de)
AP (1) AP2000001801A0 (de)
AR (1) AR011229A1 (de)
AT (1) ATE273990T1 (de)
AU (1) AU2048399A (de)
BR (1) BR9813976A (de)
CA (1) CA2309200A1 (de)
CO (1) CO5021135A1 (de)
DE (1) DE69825780T2 (de)
EA (1) EA200000392A1 (de)
EE (1) EE200000285A (de)
ES (1) ES2222621T3 (de)
GB (1) GB9723589D0 (de)
HR (1) HRP20000275A2 (de)
HU (1) HUP0004082A2 (de)
IL (1) IL135964A0 (de)
IS (1) IS5477A (de)
MA (1) MA26565A1 (de)
NO (1) NO20002361L (de)
PE (1) PE20000013A1 (de)
PL (1) PL340921A1 (de)
SK (1) SK6722000A3 (de)
TR (1) TR200002131T2 (de)
WO (1) WO1999024449A2 (de)
ZA (1) ZA9810125B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (de) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-Substituierte Adenosin Derivate und ihre Verwendung als pharmazeutische Mittel
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
WO2004016635A2 (en) * 2002-08-15 2004-02-26 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1794162A1 (de) * 2004-09-09 2007-06-13 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Purinderivate als a3- und a1-adenosinrezeptor-agonisten
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
AU2009204084A1 (en) * 2008-01-09 2009-07-16 Trovis Pharmaceuticals Llc Intrathecal treatment of neuropathic pain with A2AR agonists
EP2231642B1 (de) 2008-01-11 2013-10-23 Novartis AG Pyrimidine als kinasehemmer
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (de) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclische verbindungen und ihre verwendung
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (de) 2013-03-15 2016-08-10 Intellikine Llc Kombination von kinaseinhibitoren und verwendungen davon
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
KR20250121114A (ko) 2022-12-16 2025-08-11 아스트라제네카 아베 2,6,9-삼치환된 퓨린

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
PL340921A1 (en) 2001-03-12
AR011229A1 (es) 2000-08-02
EP1030857A2 (de) 2000-08-30
BR9813976A (pt) 2000-09-26
CA2309200A1 (en) 1999-05-20
NO20002361L (no) 2000-07-05
HRP20000275A2 (en) 2000-12-31
ZA9810125B (en) 2000-05-05
CN1285843A (zh) 2001-02-28
PE20000013A1 (es) 2000-01-21
HUP0004082A2 (hu) 2001-04-28
US6455510B1 (en) 2002-09-24
AP2000001801A0 (en) 2000-06-30
ES2222621T3 (es) 2005-02-01
WO1999024449A2 (en) 1999-05-20
MA26565A1 (fr) 2004-12-20
EP1457495A1 (de) 2004-09-15
IL135964A0 (en) 2001-05-20
TR200002131T2 (tr) 2001-01-22
GB9723589D0 (en) 1998-01-07
JP2001522857A (ja) 2001-11-20
CO5021135A1 (es) 2001-03-27
EA200000392A1 (ru) 2000-12-25
EP1030857B1 (de) 2004-08-18
SK6722000A3 (en) 2001-01-18
KR20010031875A (ko) 2001-04-16
WO1999024449A3 (en) 1999-08-19
DE69825780D1 (de) 2004-09-23
DE69825780T2 (de) 2005-01-13
EE200000285A (et) 2001-08-15
IS5477A (is) 2000-05-03
AU2048399A (en) 1999-05-31
NO20002361D0 (no) 2000-05-05

Similar Documents

Publication Publication Date Title
DE69825779D1 (de) Adenosin a1-rezeptor agonisten
ATE242259T1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
ATA904399A (de) Adenosin a3-rezeptor-modulatoren
EP0984779A4 (de) Somatostatin agonisten
DE60007127D1 (de) N-pyrazol a2a rezeptor agonisten
DE60002722D1 (de) C-pyrazol a2a rezeptor agonisten
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
PT1090019E (pt) Derivados de adenosina
EP0977751A4 (de) Somatostatin-agonisten
EP1023061A4 (de) Somatostatinagoniste
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
NO961887D0 (no) -adrenergiske agonister
DE69734833D1 (de) Vitronektin rezeptor antagonisten
DE69835024D1 (de) Allosterische adenosin-rezeptor-modulatore
NO994850D0 (no) Farmakologiske midler
DE69506826D1 (de) 5-HT4 Rezeptoragonisten
ATE231508T1 (de) Azyklische nukleosidderivate
DE60005507D1 (de) Oral aktive a1 adenosin rezeptor agonisten
FI951500L (fi) 2-substituoituja adenosiineja, joilla on A-2-reseptoriaffiniteetti
FI955257A7 (fi) 8-substituoidut-ksantiinit valikoivina adenosiinireseptoriaineina
HK1028408A (en) Adenosine a1 receptor agonists
HK1028407A (en) Adenosine a1 receptor agonists
SE9704276D0 (sv) New thermal analysis system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties